Inotiv, Inc. (NOTV)

In the past six months, Inotiv, Inc.'s stock price has significantly declined. Key events include the release of Q4 FY25 financial results, a partnership with VUGENE, a partnership with LifeNet Health, and the release of Q1 FY26 financial results, which led to a stock price drop. A cybersecurity incident was reported, leading to a slight increase in stock price. Ernst & Young issued a "going concern" warning in Inotiv's FY2025 10-K, indicating financial stress.

Inotiv experiences some demand seasonality, particularly within its Research Models and Services (RMS) segment. The first fiscal quarter is typically characterized by weaker seasonality for the RMS business. The Discovery and Safety Assessment (DSA) business demonstrated strong year-over-year revenue growth in Q1 FY26, offsetting the seasonal weakness in RMS.

Inotiv, Inc. is a contract research organization specializing in nonclinical and analytical drug discovery and development services. The company aims to enhance efficiency, improve data quality, and reduce development costs for new drugs and medical devices. Inotiv operates in the Health Care sector, divided into Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment provides preclinical services and manufactures scientific instruments, while the RMS segment offers research models and produces lab animal diets and bedding.

Inotiv, Inc. has a global presence with operations in the United States and the Netherlands. Its headquarters are located in West Lafayette, Indiana, United States.

In the past year, Inotiv's brand reputation has been impacted by a cybersecurity incident and a "going concern" warning. The cybersecurity incident led to the potential acquisition of sensitive personal information. The "going concern" warning, coupled with repeated instances of needing lender waivers, suggests significant financial challenges.

Inotiv, Inc. has a diverse ownership structure including institutional, insider, and retail investors. Major institutional owners include Balyasny Asset Management Llc and Vanguard Group Inc. Key individual and insider owners include P2 Capital Partners LLC, John E. Sagartz, and Robert W. Leasure Jr.